Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:
聖地亞哥,2024年11月18日(環球新聞社)-- Skye Bioscience, Inc.(納斯達克股票代碼:SKYE)("Skye"),一家專注於爲代謝健康開闢新療法途徑的臨床階段生物製藥公司,今日宣佈將參加以下即將舉行的醫療投資會議:
- Evercore HealthCONx Conference (Miami)
Fireside chat, Tuesday, December 3, 2:10 pm ET + 1x1 meetings
- Evercore HealthCONx會議(邁阿密)
爐邊聊天,週二,12月3日,美國東部時間下午2:10 + 1對1會議
- Citi Global Healthcare Conference (Miami)
Thursday, December 5, 1x1 meetings
- Citi全球醫療保健會議(邁阿密)
週四,12月5日,1對1會議
- Piper Sandler Annual Healthcare Conference (New York City)
Fireside chat, Thursday, December 5, 11:30 am ET + 1x1 meetings
- 派傑投資年度醫療保健會議(紐約市)
爐邊聊天,週四,12月5日,美國東部時間上午11:30 + 1對1會議
Available webcasts will be accessible on Skye's website.
可通過斯凱的網站觀看網絡直播 網站.
About Skye Bioscience
關於Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). For more information, please visit: . Connect with us on X and LinkedIn.
Skye專注於通過開發調節G蛋白偶聯受體的下一代分子,爲代謝健康開闢新的治療途徑。Skye的策略利用人體已驗證具有顯著機理證據的生物學靶點,開發第一類治療藥物,具有臨床和商業差異。Skye正在進行第2期臨床試驗(ClinicalTrials.gov: NCT06577090)用於肥胖的nimacimab,一種在外周抑制CB1的負向變構抗體。該研究還評估了nimacimab與GLP-1R激動劑(Wegovy)的聯合應用。欲了解更多信息,請訪問: 。在X 和 LinkedIn.
CONTACTS
聯繫人
Investor Relations
ir@skyebioscience.com
(858) 410-0266
投資者關係
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
LifeSci Advisors,Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
媒體諮詢
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: statements regarding our product development, statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, statements relating to any expectations regarding the safety, including lack of neurosphyciatric effects, efficacy, tolerability or dosing of nimacimab, including based on preclinical models and the clinical information from the nimacimab Phase 1 study in NAFLD, statements regarding the ability of nimacimab to treat obesity or related indications, statements regarding the timing of receipt of interim and final data from Skye's Phase 2 obesity study of nimacimab and statements regarding the therapeutic potential of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the "Risk Factors" section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
前瞻性聲明
本新聞稿包含根據1933年修訂版本第27A條和1934年修訂版本第21E條《證券法》的前瞻性聲明。在某些情況下,前瞻性聲明可通過術語識別,包括"預期","計劃","目標","重點","目的","打算","相信","能","可以","挑戰","可預測","將","會","可能"或這些術語的否定形式或其他類似術語。這些前瞻性聲明包括但不限於:關於我們產品開發的聲明,關於尼瑪西麥單抗相對於其他小分子CB1抑制劑具有優越的安全性和耐受性剖面的聲明,關於尼瑪西麥單抗的安全性(包括缺乏神經精神效應),功效,耐受性或用藥劑量的任何期望的聲明,包括基於前臨床模型和NAFLD尼瑪西麥單抗1期研究的臨床信息,關於尼瑪西麥單抗治療肥胖或相關適應症的聲明,關於來自Skye尼瑪西麥單抗2期肥胖研究的中期和最終數據收到時間的聲明,以及關於尼瑪西麥單抗的治療潛力的聲明。此類聲明以及本新聞稿中的其他非歷史事實描述的聲明都是根據管理層當前的期望和假設,受到風險和不確定性的影響。如果這些風險或不確定性變爲現實,或這些假設被證明不正確,我們的業務、運營結果、財務狀況和股票價格可能會受到重大負面影響。我們在一個快速變化的環境中運營,新的風險不時出現。因此,我們的管理層無法預測所有風險,也無法評估所有因素對我們業務的影響或任何因素或組合因素可能導致實際結果與公司可能發表的任何前瞻性聲明中所包含內容大不相同的程度。導致實際結果可能大不相同的風險和不確定性包括但不限於我們的資本資源,關於未來測試和開發工作結果的不確定性以及在公司向美國證券交易委員會的定期文件中描述的其他風險,包括Skye的最新年度報告Form 10-k和季度報告Form 10-Q"風險因素"部分中的風險。除非法律明文要求,Skye否認更新這些前瞻性聲明的任何意圖或義務。